Paola Aimone

3.0k total citations · 1 hit paper
43 papers, 1.1k citations indexed

About

Paola Aimone is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Paola Aimone has authored 43 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 15 papers in Genetics and 13 papers in Molecular Biology. Recurrent topics in Paola Aimone's work include Chronic Myeloid Leukemia Treatments (18 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Neuroendocrine Tumor Research Advances (8 papers). Paola Aimone is often cited by papers focused on Chronic Myeloid Leukemia Treatments (18 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Neuroendocrine Tumor Research Advances (8 papers). Paola Aimone collaborates with scholars based in Switzerland, United States and Italy. Paola Aimone's co-authors include Emmanuelle di Tomaso, Cristian Massacesi, Cornelia Quadt, Caroline Germa, Bharani Dharan, Nathalie Fretault, Ranjana Tavorath, Samit Hirawat, Patrick Urban and Lucia Trandafir and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Paola Aimone

43 papers receiving 1.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

2024 113 citations Simron Singh, Daniel Halperin et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paola Aimone Switzerland	17	549	372	338	240	235	43	1.1k
Francesco Turturro United States	19	637 1.2×	580 1.6×	159 0.5×	80 0.3×	412 1.8×	64	1.4k
Ann M. Lowe United States	9	253 0.5×	414 1.1×	174 0.5×	157 0.7×	252 1.1×	11	1.4k
Eugenio Villa Italy	14	676 1.2×	215 0.6×	396 1.2×	114 0.5×	59 0.3×	20	973
Andreas H. Marx Germany	26	1.3k 2.3×	698 1.9×	822 2.4×	129 0.5×	170 0.7×	75	2.2k
Teresa Alonso‐Gordoa Spain	19	619 1.1×	366 1.0×	343 1.0×	333 1.4×	40 0.2×	82	1.2k
Joanne Lager United States	17	439 0.8×	563 1.5×	389 1.2×	32 0.1×	296 1.3×	37	1.2k
B.Y. Yeap United States	20	805 1.5×	563 1.5×	1.0k 3.0×	67 0.3×	185 0.8×	65	2.0k
Yanzhi Hsu United States	16	340 0.6×	108 0.3×	429 1.3×	73 0.3×	79 0.3×	42	891
Jacob B. Allred United States	20	661 1.2×	1.1k 2.9×	135 0.4×	129 0.5×	709 3.0×	67	1.7k
Kevin Yee United States	9	303 0.6×	480 1.3×	362 1.1×	35 0.1×	499 2.1×	12	1.2k

Countries citing papers authored by Paola Aimone

Since Specialization

Citations

This map shows the geographic impact of Paola Aimone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paola Aimone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paola Aimone more than expected).

Fields of papers citing papers by Paola Aimone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paola Aimone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paola Aimone. The network helps show where Paola Aimone may publish in the future.

Co-authorship network of co-authors of Paola Aimone

This figure shows the co-authorship network connecting the top 25 collaborators of Paola Aimone. A scholar is included among the top collaborators of Paola Aimone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paola Aimone. Paola Aimone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gaze, Mark N., Daria Handkiewicz-Junak, Raquel Hladun, et al.. (2025). Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. European Journal of Nuclear Medicine and Molecular Imaging. 52(11). 4001–4015. 6 indexed citations

Singh, Simron, Daniel Halperin, Sten Myrehaug, et al.. (2024). [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet. 403(10446). 2807–2817. 113 indexed citations breakdown →

Menda, Yusuf, Jordi Rodón, Ajit H. Goenka, et al.. (2024). 671P LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors. Annals of Oncology. 35. S526–S526. 6 indexed citations

Radich, Jerald P., Andreas Hochhaus, Tamás Masszi, et al.. (2021). Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 35(5). 1344–1355. 47 indexed citations

Hijiya, Nobuko, Alexey Maschan, Carmelo Rizzari, et al.. (2021). A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Advances. 5(14). 2925–2934. 19 indexed citations

Chowdhury, Simon, J. Infante, Robert D. Hawkins, et al.. (2021). A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 19(5). 434–446. 19 indexed citations

Cortes, Jörge E., Timothy P. Hughes, Michael J. Mauro, et al.. (2020). Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. Blood. 136(Supplement 1). 47–50. 37 indexed citations

Gelderblom, Hans, Robin L. Jones, Suzanne George, et al.. (2020). Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. British Journal of Cancer. 122(8). 1158–1165. 21 indexed citations

Hughes, Timothy P., Michael J. Mauro, Dong‐Wook Kim, et al.. (2020). CML-121: Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs). Clinical Lymphoma Myeloma & Leukemia. 20. S235–S235. 3 indexed citations

10.

Hijiya, Nobuko, Alexey Maschan, Carmelo Rizzari, et al.. (2019). Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia. Blood. 134(23). 2036–2045. 37 indexed citations

11.

Mauro, Michael J., Andreas Hochhaus, Carla Boquimpani, et al.. (2019). A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology. 37(15_suppl). TPS7070–TPS7070. 3 indexed citations

12.

Mauro, Michael J., Andreas Hochhaus, Carla Boquimpani, et al.. (2019). A Multicenter, Randomized Phase 3 Study of Asciminib (ABL001) vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 TKIs. Clinical Lymphoma Myeloma & Leukemia. 19. S286–S287. 2 indexed citations

13.

Ross, David M., Tamás Masszi, Andrzej Hellmann, et al.. (2019). PF409 DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER STOPPING FRONTLINE (1L) NILOTINIB: ENESTFREEDOM 192‐WK RESULTS. HemaSphere. 3(S1). 157–157. 2 indexed citations

14.

Mauro, Michael J., D.-W. Kim, Jörge E. Cortes, et al.. (2019). S884 COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY. HemaSphere. 3(S1). 397–398. 13 indexed citations

15.

Sternberg, Cora N., Frede Donskov, Naomi B. Haas, et al.. (2018). Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. Clinical Cancer Research. 24(13). 3005–3013. 45 indexed citations

16.

Chowdhury, Simon, David F. McDermott, Martin H. Voss, et al.. (2017). A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology. 35(15_suppl). 4506–4506. 67 indexed citations

17.

Fazio, Nicola, Roberto Buzzoni, Éric Baudin, et al.. (2016). A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.. PubMed. 36(2). 713–9. 73 indexed citations

18.

Massacesi, Cristian, Emmanuelle di Tomaso, Patrick Urban, et al.. (2016). PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. OncoTargets and Therapy. 9. 203–203. 195 indexed citations

19.

Vansteenkiste, Johan, Jean‐Luc Canon, Filippo de Braud, et al.. (2015). Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 10(9). 1319–1327. 123 indexed citations

20.

Bolis, Giorgio, Giovanna Scarfone, Francesco Raspagliesi, et al.. (2010). Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III–IV epithelial ovarian cancer a multicenter, randomized study. European Journal of Cancer. 46(16). 2905–2912. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact